In Part 3 of the ‘Optimizing Dosing Strategy for Late-Line Therapies in mCRC’ roundtable discussion, Drs. Grothey, Bekaii-Saab, and Van Cutsem discuss the results of the REVERCE trial on therapeutic sequencing and expound upon emerging therapies for the refractory mCRC population, including HER-targeted and immunotherapies.
Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=CRC
© 2018 Imedex, LLC.
Advertisement